We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seattle Genetics, Astellas Report Positive Cancer Study Data
Read MoreHide Full Article
Seattle Genetics, Inc. along with Japanese partner Astellas Pharma, Inc announced positive top-line results from the first cohort of the phase II EV-201 study on enfortumab vedotin. The candidate is being evaluated in the pivotal study for the treatment of patients with advanced/metastatic urothelial cancer who were previously treated with both a checkpoint inhibitor (PD-1/PD-L1) and platinum-based chemotherapy.
Both the companies plan to submit a biologics license application (BLA) for enfortumab vedotin to the FDA later this year.
Results from this study demonstrated a 44% objective response rate (ORR), per blinded independent central review. Moreover, the duration of response was similar to that of the previously reported data from phase I EV-101 study. The companies plan to present this data at an upcoming medical meeting.
Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) targeting Nectin-4, a cell adhesion molecule that is expressed in many solid tumors.
We would like to remind investors that, in July 2018, Seattle Genetics and Astellas initiated the phase III EV-301 study on enfortumab vedotin in patients with advanced urothelial cancer who previously received both a checkpoint inhibitor (PD-1/PD-L1) and platinum-based chemotherapy. Both the companies also completed the cohort enrollment in EV-201 study for the same.
The phase III EV-301 study will support the regulatory filing for potential approval of the candidate. The companies continue to evaluate EV combined with Merck’s (MRK - Free Report) Keytruda in first-line setting.
Notably, Enfortumab vedotin was granted Breakthrough Therapy designation by the FDA for the given indication in March 2018.
Shares of Seattle Genetics have rallied 26.8% so far this year, outperforming the industry’s increase of 9.6%.
Apart from enfortumab vedotin, pipeline candidates in Seattle Genetics’ portfolio include tisotumab vedotin and SEA-BCMA. The company along with Danish company, Genmab A/S (GNMSF - Free Report) is evaluating tisotumab vedotin in the pivotal innovaTV 204 study for the treatment of patients with recurrent/metastatic cervical cancer whose disease have relapsed or progressed after standard of care treatment. Both the companies expect to complete enrollment in the study by mid-2019.
Last November, Seattle Genetics initiated dosing in the phase I study on pipeline candidate, SEA-BCMA. The early-stage candidate is currently being evaluated for the treatment of patients with relapsed or refractory multiple myeloma (MM).
Zacks Rank & Key Pick
Seattle Genetics currently carries a Zacks Rank #5 (Strong Sell).
Celgene’s earnings estimates have been revised 3.5% upward for 2019 and 3.3% for 2020 over the past 60 days. The stock has surged 36.4% in the year so far.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Seattle Genetics, Astellas Report Positive Cancer Study Data
Seattle Genetics, Inc. along with Japanese partner Astellas Pharma, Inc announced positive top-line results from the first cohort of the phase II EV-201 study on enfortumab vedotin. The candidate is being evaluated in the pivotal study for the treatment of patients with advanced/metastatic urothelial cancer who were previously treated with both a checkpoint inhibitor (PD-1/PD-L1) and platinum-based chemotherapy.
Both the companies plan to submit a biologics license application (BLA) for enfortumab vedotin to the FDA later this year.
Results from this study demonstrated a 44% objective response rate (ORR), per blinded independent central review. Moreover, the duration of response was similar to that of the previously reported data from phase I EV-101 study. The companies plan to present this data at an upcoming medical meeting.
Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) targeting Nectin-4, a cell adhesion molecule that is expressed in many solid tumors.
We would like to remind investors that, in July 2018, Seattle Genetics and Astellas initiated the phase III EV-301 study on enfortumab vedotin in patients with advanced urothelial cancer who previously received both a checkpoint inhibitor (PD-1/PD-L1) and platinum-based chemotherapy. Both the companies also completed the cohort enrollment in EV-201 study for the same.
The phase III EV-301 study will support the regulatory filing for potential approval of the candidate. The companies continue to evaluate EV combined with Merck’s (MRK - Free Report) Keytruda in first-line setting.
Notably, Enfortumab vedotin was granted Breakthrough Therapy designation by the FDA for the given indication in March 2018.
Shares of Seattle Genetics have rallied 26.8% so far this year, outperforming the industry’s increase of 9.6%.
Apart from enfortumab vedotin, pipeline candidates in Seattle Genetics’ portfolio include tisotumab vedotin and SEA-BCMA. The company along with Danish company, Genmab A/S (GNMSF - Free Report) is evaluating tisotumab vedotin in the pivotal innovaTV 204 study for the treatment of patients with recurrent/metastatic cervical cancer whose disease have relapsed or progressed after standard of care treatment. Both the companies expect to complete enrollment in the study by mid-2019.
Last November, Seattle Genetics initiated dosing in the phase I study on pipeline candidate, SEA-BCMA. The early-stage candidate is currently being evaluated for the treatment of patients with relapsed or refractory multiple myeloma (MM).
Zacks Rank & Key Pick
Seattle Genetics currently carries a Zacks Rank #5 (Strong Sell).
A better-ranked stock in the healthcare sector is Celgene Corp. , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Celgene’s earnings estimates have been revised 3.5% upward for 2019 and 3.3% for 2020 over the past 60 days. The stock has surged 36.4% in the year so far.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>